Adial Pharmaceuticals
ADIL
11 hedge funds and large institutions have $194K invested in Adial Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.15% less ownership
Funds ownership: 0.27% → 0.12% (-0.15%)
21% less funds holding
Funds holding: 14 → 11 (-3)
40% less capital invested
Capital invested by funds: $326K → $194K (-$132K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$28.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.89K |
| 4 |
Morgan Stanley
New York
|
+$261 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$82.6K |
| 2 |
Renaissance Technologies
New York
|
-$39.5K |
| 3 |
HF
HRT Financial
New York
|
-$33K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.75K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$678 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MCM
1
Manchester Capital Management
Manchester,
Vermont
| $48K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $45.4K | +$20.4K | +784 | +76% |
|
|
3
Citadel Advisors
Miami,
Florida
| $33.2K | +$8.89K | +341 | +34% |
|
4
BlackRock
New York
| $27.7K | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| $27.1K | +$28.3K | +1,085 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $4.4K | -$82.6K | -3,168 | -95% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $3.94K | -$1.75K | -67 | -30% |
|
|
1IA
8
1620 Investment Advisors
Plymouth,
Massachusetts
| $3.6K | – | – | – |
|
|
9
Morgan Stanley
New York
| $309 | +$261 | +10 | +500% |
|
|
10
Bank of America
Charlotte,
North Carolina
| $52 | -$678 | -26 | -93% |
|
|
AWM
11
Abound Wealth Management
Franklin,
Tennessee
| $27 | – | – | – |
|
|
12
Renaissance Technologies
New York
| – | -$39.5K | -1,374 | Closed |
|
|
HF
13
HRT Financial
New York
| – | -$33K | -1,169 | Closed |
|
14
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$10 | – | – |
|
ADIL Hedge Fund Activity: Q3 2024 in Review
11 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2024, worth a combined $194K — down 40% from $326K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADIL and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $28.3K. The largest seller was UBS Group, cutting an estimated $82.6K.
- 11 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2024, down from 14 in Q2 2024.
- Funds reported $194K of Adial Pharmaceuticals stock for Q3 2024, down 40% quarter-over-quarter.
- 1 fund opened new Adial Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of -2 holders.
- The largest Adial Pharmaceuticals buyer in Q3 2024 was Two Sigma Securities, an estimated $28.3K added.
- The largest Adial Pharmaceuticals seller in Q3 2024 was UBS Group, an estimated $82.6K sold.
Based on aggregated 13F filings for Q3 2024.